Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study

Japanese Heart Journal

Volumn 37, Issue 3, 1996, Pages 353-359

  Wagdi, Philipp ^a,b   Fluri, Martin ^a   Aeschbacher, Beat ^a   Fikrle, Anton ^a   Meier, Bernhard ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Antioxidants; Cardioprotection; Cardiotoxicity; Chemotherapy; Radiotherapy

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DOXORUBICIN;

ADULT; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; MALE; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

EID: 0030054863     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.37.353     Document Type: Article

References (14)

1. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis, 1991; 33: 299-312.
2. Doroshow JH : Doxorubicin-induced cardiac toxicity (Editorial). New Engl J Med 1991; 324: 843-9.
3. Von Hoff DD, Rosenzweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982; 9: 23-33
4. Merrill J, Greco FA, Zimbler H, Brereton HD, Lamberg JD, Pomeroy TC. Adriamycin and radiation: synergistic cardiotoxicity. Letter to the Editor. Ann Intern Med 1975; 82: 122-3.
5. Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy - risk factors. Cancer 1977; 39: 1397-402.
6. Ganey PE, Carter LS, Muller RA, Thurman RG. Doxombicin toxicity in perfused rat heart. Circ Res 1991; 68: 1610-8.
7. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N- acetylcysteine. J Clin Invest, 1981; 68: 1053-64.
8. Milei J, Boveris A, Llesuy S, et al. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am Heart J 1986, 111, 95-102.
9. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52.
10. Spirito P, Maron BJ, Bonow RO. Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques. J Am Coll Cardiol 1986; 7: 518-26
11. Mahmarian JH, Moye L, Verani MS, Eaton T, Francis M, Pratt CG. Criteria for the accurate interpretation of changes in left ventricular ejection fraction and cardiac volumes as assessed by rest and exercise gated radionuclide angiography. J Am Coll Cardiol 1991; 18: 112-9.
12. Halliwell B. Reactive oxygen species in living systems: Source, biochemistry and role in human disease. Am J Med 1991: 91 Suppl 3C: 3C-14S- 22S
13. Ferrari R, Ceconi C, et al. Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. Am J Med 1991; 91 (Suppl 3C): 3C- 95 S-3C-105 S.
14. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27.